Moore MJ - Search Results

1

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. Winquist E, et al. Among authors: moore mj. Urol Oncol. 2005 May-Jun;23(3):143-9. doi: 10.1016/j.urolonc.2004.12.012. Urol Oncol. 2005. PMID: 15907712 Clinical Trial.

2

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.

Bélanger K, Moore M, Baker SD, Dionne J, Maclean M, Jolivet J, Siu L, Soulières D, Wainman N, Seymour L. Bélanger K, et al. J Clin Oncol. 2002 May 15;20(10):2567-74. doi: 10.1200/JCO.2002.12.047. J Clin Oncol. 2002. PMID: 12011137 Clinical Trial.

3

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.

Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. Tolcher AW, et al. Clin Cancer Res. 2002 Aug;8(8):2530-5. Clin Cancer Res. 2002. PMID: 12171880 Clinical Trial.

4

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer.

Juffs HG, Moore MJ, Tannock IF. Juffs HG, et al. Among authors: moore mj. Lancet Oncol. 2002 Dec;3(12):738-47. doi: 10.1016/s1470-2045(02)00930-0. Lancet Oncol. 2002. PMID: 12473515 Review.

5

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.

Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Stadler WM, et al. Urol Oncol. 2002 Jul-Aug;7(4):153-7. doi: 10.1016/s1078-1439(02)00182-5. Urol Oncol. 2002. PMID: 12474531 Clinical Trial.

6

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Knox JJ, et al. Among authors: moore mj. J Clin Oncol. 2005 Apr 1;23(10):2332-8. doi: 10.1200/JCO.2005.51.008. J Clin Oncol. 2005. PMID: 15800324 Clinical Trial.

7

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.

Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Lê LH, et al. Among authors: moore mj. Cancer Chemother Pharmacol. 2005 Aug;56(2):154-60. doi: 10.1007/s00280-004-0942-7. Epub 2005 Apr 5. Cancer Chemother Pharmacol. 2005. PMID: 15809877 Clinical Trial.

8

Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.

Ernst DS, Brasher P, Venner PM, Czaykowski P, Moore MJ, Reyno L, Winquist E, Segal R, Hao D. Ernst DS, et al. Among authors: moore mj. Can J Urol. 2005 Apr;12(2):2575-80. Can J Urol. 2005. PMID: 15877938

9

A Phase II study of oxaliplatin in urothelial cancer.

Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM. Winquist E, et al. Among authors: moore mj. Urol Oncol. 2005 May-Jun;23(3):150-4. doi: 10.1016/j.urolonc.2004.11.008. Urol Oncol. 2005. PMID: 15907713 Clinical Trial.

10

A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.

Tinker A, Winquist E, Canil C, Moore M, Murray RN, Chi KN. Tinker A, et al. Am J Clin Oncol. 2006 Feb;29(1):3-7. doi: 10.1097/01.coc.0000200044.81711.57. Am J Clin Oncol. 2006. PMID: 16462494 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

805 results

Search Page

Filters